P007 Hidradenitis Suppurativa: Case-Based Clinical Pearls
DESCRIPTION
Key updates in the field of hidradenitis suppurativa will be highlighted. Management strategies for both patients with milder HS and for those who are biologic and small molecule inhibitor candidates will be discussed. Discussion topics include how to approach layering therapy, choosing the first biologic, and multi-biologic failure. HS procedures that a dermatologist can perform in their office will be outlined. Off-label and pipeline therapies including GLP-1 agonists will be covered. This session will provide tips to the practicing dermatologist on how to optimize their care for patients with HS that are relevant to real-world practice.
LEARNING OBJECTIVES
Utilize up-to-date evidence to optimize management of patients who have milder HS, patients who are biologic and small molecule inhibitor candidates, and patients who have failed multiple treatments
Incorporate HS procedures into your practice
Identify off-label strategies and pipeline therapies for HS
SCHEDULE
8:45 AM
My patient has milder HS: What can I offer them?
Katrina Lee, MD, FAAD
8:55 AM
Reconceptualizing "Moderate" HS disease
Amit Garg, MD, FAAD
9:10 AM
Biologics and Small Molecule Inhibitors for HS
Vivian Shi, MD, FAAD
9:25 AM
Dual Biologic Therapy or Biologic plus JAK inhibitor therapy for HS
Jennifer Lin Hsiao, MD, FAAD
9:40 AM
HS Procedures and Wound Care Tips
Steven Daniel Daveluy, MD, FAAD
10:00 AM
GLP-1 agonists for HS
Jonathan W. Rick, MD, FAAD
10:10 AM
On the Horizon: What's Next for HS Therapies?
Natalie Fragoso, MD, FAAD
10:25 AM
Q&A
DIRECTOR
Jennifer Lin Hsiao, MD, FAAD
CO-DIRECTOR
Vivian Shi, MD, FAAD
University of Washington, Seattle
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Wayne State University
Natalie Fragoso, MD, FAAD
Dartmouth Health
Amit Garg, MD, FAAD
Northwell Health
Katrina Lee, MD, FAAD
Jonathan W. Rick, MD, FAAD
University of California, Davis
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Natalie Fragoso, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Insmed Incorporated – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Target-Derm – Investigator(Grants/Research Funding); UCB Pharma – Consultant (1099 relationship)(Fees);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Data Safety Monitoring Board(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Jonathan W. Rick, MD, FAAD
Incyte Corporation – Consultant (1099 relationship)(Fees);
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);